Introduction
============

A glioma is a tumour produced by glial cells and is the most common primary malignant tumour in the central nervous system, accounting for \~30% of the tumours in this region ([@b1-ol-0-0-11514],[@b2-ol-0-0-11514]). Astrocytoma is one of the most aggressive gliomas, with a poor prognosis ([@b3-ol-0-0-11514],[@b4-ol-0-0-11514]). Astrocytomas can be found in various parts of the central nervous system and are a common neuroepithelial tumour that can occur in individuals of all ages ([@b5-ol-0-0-11514]). The average survival time ranges from 17 weeks to 3 years ([@b6-ol-0-0-11514]). The tumours develop slowly and progressively, and epilepsy is often the first symptom. Approximately 50% of patients experience the onset of epilepsy and the majority of patients experience headaches, psychomotor muscle weakness, vomiting and an obvious disturbance of consciousness ([@b7-ol-0-0-11514]).

According to the 2016 World Health Organization (WHO) classification, astrocytoma can be divided into four grades (I--IV) based on its histological and morphological characteristics ([@b8-ol-0-0-11514]): Low-grade astrocytomas are classified as grades I and II, and high-grade astrocytomas are classified as grades III and IV. The prognosis of high-grade astrocytoma is very poor and the average survival time is only 0.6--0.7 years ([@b9-ol-0-0-11514]).

The growth pattern of astrocytomas in the brain consists of invasive or local invasive growth, and as the invasiveness increases, the tumour grade increases and the survival rate decreases ([@b10-ol-0-0-11514]). At present, the conventional treatment is primarily surgical resection supplemented by radiotherapy and chemotherapy ([@b11-ol-0-0-11514]). There are a number of surgical methods for astrocytoma, including excisional biopsy (EB), subtotal resection (STR), gross resection (GR), partial resection (PR) and gross total resection (GTR). Although the efficacy of conventional treatment has made some progress in recent years, the prognosis for astrocytoma patients is still poor, which is primarily associated with incomplete resection, recurrence and radiotherapy and chemotherapy resistance after surgical resection ([@b12-ol-0-0-11514]--[@b14-ol-0-0-11514]). Therefore, it is important to find an optimal treatment for patients with astrocytoma.

The purpose of the present study was to use the Surveillance, Epidemiology and End Results (SEER) database to characterize the different therapies for patients with astrocytoma at a population level and the recommendations for treatment use.

Patients and methods
====================

### Data source and patients

The SEER database includes \~28% of the US population and collects demographic information, primary tumour location, tumour grade, tumour stage, treatment method and survival time data for patients with cancer ([@b15-ol-0-0-11514]). The National Cancer Institute SEER\*Stat software \[version 8.3.5; SEER 18 Regs Custom Data (with additional treatment field), Nov 2017 Sub (1973--2015 varying) database\] was used to identify 46,717 patients diagnosed with astrocytoma between January 2004 and December 2015. Histological ICD-O-3 codes (The 3rd edition of The International Classification of Diseases for Oncology) ([@b16-ol-0-0-11514]) were used to select the following subtypes: Subependymal giant cell astrocytoma, malignant (ICD-O-3 code 9384/3); astrocytoma, NOS (ICD-O-3 code 9400/3); astrocytoma, anaplastic (ICD-O-3 code 9401/3); protoplasmic astrocytoma (ICD-O-3 code 9410/3); gemistocytic astrocytoma (ICD-O-3 code 9411/3); fibrillary astrocytoma (ICD-O-3 code 9420/3); pilocytic astrocytoma, malignant (ICD-O-3 code 9421/3); pleomorphic xanthoastrocytoma (ICD-O-3 code 9424/3); glioblastoma, NOS (ICD-O-3 code 9440/3); giant cell glioblastoma (ICD-O-3 code 9441/3); and gliosarcoma (ICD-O-3 code 9442/3).

The exclusion criteria in the present study were: i) Unknown survival time (n=206); ii) unknown household income (n=2); iii) age \<18 years (n=3,597); and surgical code not 00, 20, 21, 30, 40 or 55 (n=688; <http://seer.cancer.gov/manuals/2018/AppendixC/Surgery_Codes_Brain_2018.pdf>). Ultimately, a total of 42,224 eligible patients diagnosed with astrocytoma.

There were several methods used to confirm the diagnosis of patients in the SEER database, such as histological diagnosis and radiography. Overall, 90.7% of patients were confirmed by positive histological diagnosis and 7.8% by radiography ([Fig. S1](#SD1-ol-0-0-11514){ref-type="supplementary-material"}).

### Study variables

The study variables in the present study included age at diagnosis, year of diagnosis, sex, ethnicity, marital status, urban-rural residence, household income, summary stage, and surgical, radiotherapy and chemotherapy information. According to the surgical code, patients were divided into four groups: No surgery (code 00), EB (code 20), STR (code 21), GR (code 30), PR (code 40) and GTR (code 55) ([@b17-ol-0-0-11514]). Astrocytomas were divided into four groups according to the 2016 WHO classification: Grade I, grade II, grade III and grade IV ([@b8-ol-0-0-11514]). Demographic and clinicopathological characteristics included age at diagnosis (18--40, 41--60, 61--80 and \>80 years), sex (male and female), ethnicity (white, black and other), marital status (married, unmarried and unknown), urban-rural residence (metropolitan and non-metropolitan), summary stage (localized, regional, distant and unstaged/unknown), radiotherapy (yes or no) and chemotherapy (yes or no). Household income was divided into three groups: Low-income group (\<4,219), middle-income group (4,219--5,191) and high-income group (\>5,191). Overall survival (OS) and cancer-specific survival (CSS) were the primary endpoints of the present study.

### Statistical analysis

The OS time corresponded to the length of time from the date of diagnosis to the death from any cause or the date on which data were censored. When analyzing CSS, mortality cases associated with other causes were excluded. SPSS version 20.0 (IBM Corp.) was used for all statistical analyses. χ^2^ tests were used to analyze factors associated with the surgical methods. Kaplan-Meier curve analyses and the log-rank test were used to analyze the OS and CSS times of patients with regard to different surgical methods and other variables. Multivariate Cox regression was used to analyze factors associated with OS and CSS. P\<0.05 was considered to indicate a statistically significant difference

Results
=======

### Demographic and clinicopathological characteristics of the astrocytoma

A total of 42,224 eligible astrocytoma patients from between January 2004 and 2015 December were included in the present study cohort. Among them, 11,427 (27.1%) patients did not receive surgery, 7,661 (18.1%) received EB, 5,520 (13.1%) received STR, 6,037 (14.3%) received GR, 5,314 (12.6%) received PR and 6,265 (14.8%) received GTR ([Fig. 1A](#f1-ol-0-0-11514){ref-type="fig"}). [Table I](#tI-ol-0-0-11514){ref-type="table"} shows the demographic and clinicopathological characteristics of patients with astrocytoma and the association between surgical method and each variable as analyzed by the χ^2^ test. χ^2^ tests showed that age of diagnosis, year of diagnosis, sex, ethnicity, marital status, urban-rural residence, household income, summary stage, radiotherapy and chemotherapy information were all associated factors (all P\<0.001). Among all 42,224 patients, over time, the number of patients diagnosed with astrocytoma increased. The majority of patients were white \[37,462 (88.7%); [Table I](#tI-ol-0-0-11514){ref-type="table"}\], between 41--80 years old \[33,344 (79.0%)\], had localized disease \[33,090 (78.4%); [Fig. 2A](#f2-ol-0-0-11514){ref-type="fig"}\] and were WHO grade IV \[32,876 (77.9%); [Fig. 2B](#f2-ol-0-0-11514){ref-type="fig"}\].

Among all 42,224 patients, the proportion of patients who underwent STR or GR increased between 2004 and 2015 \[43/3,281 patients (1.3%) vs. 957/3,871 (24.7%), P\<0.001; and 50/3,281 patients (1.5%) vs. 1,214/3,871 (31.4%), P\<0.001, respectively\]. However, the proportion of patients who did not undergo surgery, PR or GTR decreased between 2004 and 2015 \[1,000/3,281 patients (30.5%) vs. 932/3,871 (24.1%), P\<0.001; 778/3,281 patients (23.7%) vs. 57/3,871 (1.5%), P\<0.001; and 1,020/3,281 patients (31.1%) vs. 104/3,871 (2.7%), P\<0.001\] ([Fig. 3](#f3-ol-0-0-11514){ref-type="fig"}).

### Subgroup analysis for evaluating the proportion of different surgical methods based on SEER stage and grade

The proportion of different surgical methods based on summary stage and grade were evaluated. As shown in [Table I](#tI-ol-0-0-11514){ref-type="table"} and [Fig. 1B-D](#f1-ol-0-0-11514){ref-type="fig"}, compared with patients with regional and distant astrocytoma, patients with localized astrocytoma were more likely to undergo GR (16.2 vs. 7.4 or 8.6%) and GTR (16.9 vs. 7.5 or 8.2%). In addition, patients with WHO grade I and IV were more likely to undergo GR (18.9 and 14.8 vs. 11.1 and 12.6%; P\<0.001) and GTR (23.5 and 15.5 vs. 12.1 and 9.9%; P\<0.001) compared with WHO grade II and III ([Table I](#tI-ol-0-0-11514){ref-type="table"}; [Fig. 1E-H](#f1-ol-0-0-11514){ref-type="fig"}).

### Effects of different variables on OS and CSS in patients with astrocytoma

Kaplan-Meier curves were constructed to analyze the influence of clinical factors on the OS and CSS of patients with astrocytoma ([Table II](#tII-ol-0-0-11514){ref-type="table"}). Kaplan-Meier analysis showed that age at diagnosis, ethnicity, marital status, urban-rural residence, household income, summary stage, WHO grade, and surgical, radiotherapy and chemotherapy information were significantly associated with OS and CSS (all P\<0.05). Patients who underwent GR or GTR had longer OS median survival times (MSTs) (17.00 and 15.00 months) and higher CSS MST (19.00 and 17.00 months) compared with those in the other surgical groups ([Fig. 4A and B](#f4-ol-0-0-11514){ref-type="fig"}).

### Identification of prognostic factors for patients with astrocytoma

Multivariate Cox regression was used to analyze the factors associated with OS and CSS in patients with astrocytoma ([Table III](#tIII-ol-0-0-11514){ref-type="table"}). After adjusting for age at diagnosis, ethnicity, marital status, urban-rural residence, household income, summary stage, WHO grade, and surgical, radiotherapy and chemotherapy information, Cox regression indicated that compared with EB patients, the non-surgical patients \[hazard ratio (HR), 1.45; 95% confidence interval (CI), 1.41--1.50; P\<0.001) and patients with PR (HR, 1.04; 95% CI, 1.00--1.08; P=0.038) had less favorable OS, whereas patients with GR (HR, 0.72; 95% CI, 0.69--0.75; P\<0.001) and GTR (HR, 0.80; 95% CI, 0.77--0.83; P\<0.001) had more favorable OS. In terms of CSS, compared with other patients, the non-surgical patients (vs. EB; HR, 1.43; 95% CI, 1.38--1.49; P\<0.001) had significantly lower odds of CSS, whereas GR patients (vs. EB; HR, 0.72; 95% CI, 0.69--0.76; P\<0.001) and GTR patients (vs. EB; HR, 0.80; 95% CI, 0.77--0.83; P\<0.001) had significantly greater odds of CSS. Surgical method was an independent prognostic factor for OS and CSS in patients with astrocytoma.

### Subgroup analysis for evaluating the effect of surgical method on OS and CSS based on summary stage and WHO grade

Based on summary stage and WHO grade, the difference between surgical method and prognosis among the subgroups of astrocytoma patients was further examined ([Table IV](#tIV-ol-0-0-11514){ref-type="table"}). It was found that for OS and CSS, surgical method was still an independent prognostic factor for patients with localized, regional, distant, grade II, grade III and grade IV. Compared with patients with EB, patients with GTR in the localized group (OS: HR, 0.82; 95% CI, 0.79--0.86; P\<0.001; CSS: HR, 0.82, 95% CI, 0.79--0.86; P\<0.001), regional group (OS: HR, 0.68; 95% CI, 0.61--0.76; P\<0.001; CSS: HR, 0.67; 95% CI, 0.59--0.75; P\<0.001), distant group (OS: HR, 0.75; 95% CI, 0.53--1.06; P\<0.001; CSS: H, R0.69; 95% CI, 0.47--1.00; P=0.051), grade II group (OS: HR, 0.77; 95% CI, 0.66--0.90; P\<0.001; CSS: HR, 0.78; 95% CI, 0.66--0.92; P\<0.001), grade III group (OS: HR, 0.57; 95% CI, 0.48--0.68; P\<0.001; CSS: HR, 0.57; 95% CI, 0.48--0.69; P\<0.001) and grade IV group (OS: HR, 0.82; 95% CI, 0.79--0.87; P\<0.001; CSS: HR, 0.83; 95% CI, 0.79--0.86; P\<0.001) had higher relative survival rates. Moreover, in the grade II and III subgroups, GTR was associated with the highest OS and CSS MST for patients. However, for patients in the grade I subgroup, the multivariate Cox regression showed that the surgical method had no significant effect on OS or CSS (P\>0.05). The subtype stratification based on summary stage and WHO grade is graphically displayed in [Figs. 5](#f5-ol-0-0-11514){ref-type="fig"} and [6](#f6-ol-0-0-11514){ref-type="fig"}, respectively.

Discussion
==========

The present study used a large, population-based database to quantitatively compare the impact of four different surgical methods on survival in patients with astrocytoma. The effect of surgical method on OS and CSS rate in patients with astrocytoma was analyzed and it was found that surgical method was an independent prognostic factor for patients with astrocytoma. Patients in the GR and GTR groups had higher OS and CSS time MST compared with those in the non-surgical, EB and PR groups and similar results were obtained in subgroup analyses based on summary stage and grade. However, although GR and GTR had higher OS and CSS time, it was observed that the percentage of patients who underwent GTR decreased between 2004 and 2015.

Surgical resection serves a key role in the management of patients with grade I, II and III astrocytoma ([@b18-ol-0-0-11514]). For patients with grade I astrocytoma, surgical resection is usually effective and these patients rarely receive radiotherapy and chemotherapy ([@b19-ol-0-0-11514]). Johnson *et al* ([@b20-ol-0-0-11514]) retrospectively analyzed 865 adult patients with pilocytic astrocytoma aged 20 years and older, and reported that GTR was a significant predictor of survival compared with STR or biopsy. Several studies have shown that the extent of resection can affect the OS of patients with grade II and III astrocytoma ([@b21-ol-0-0-11514]--[@b23-ol-0-0-11514]). Fouladi *et al* ([@b24-ol-0-0-11514]) found that for patients with pleomorphic xanthoastrocytoma, GTR without adjuvant therapy prolonged disease control. Moreover, for patients with glioblastoma (GBM), there is evidence to support the benefit of GTR with regard to survival ([@b25-ol-0-0-11514],[@b26-ol-0-0-11514]). A large single-center study based on 1,229 patients with GBM showed that GTR significantly prolonged MST compared with incomplete resection ([@b27-ol-0-0-11514]).

In the present study, statistical analysis of all patients with astrocytoma was performed, demonstrating that GTR and GR were beneficial for the survival of astrocytoma patients and could reduce the risk of death. Subsequently, a stratified analysis based on the summary stage and WHO grade was conducted and showed that GTR was beneficial for OS and CSS. For patients with localized, regional and distant astrocytoma, GR was associated with the longest OS and CSS time MST, whereas GTR was associated with similar survival times and benefits. In the stratified analysis according to WHO stage, the benefits of GTR were more prominent compared with other analyses, and GTR could lead to the longest OS and CSS time MST in patients with grade II and III.

Maximizing the benefit of resection is a core principle of neurosurgical oncology and every effort should be made to achieve GTR during the initial surgery. The present study observed that the proportion of patients who received STR increased from 2004 to 2015. This may be since studies have shown that patients who underwent STR of thalamic and brain stem gliomas had a relatively good prognosis ([@b28-ol-0-0-11514],[@b29-ol-0-0-11514]). Minehan *et al* ([@b30-ol-0-0-11514]) studied 136 patients with spinal astrocytoma and found that 11 patients with GTR had the shortest median survival time, which may be the reason for the decrease in the proportion of patients with GTR.

In the present study of patients with astrocytoma, the mortality rate of patients treated with PR was higher compared with that of patients receiving EB, STR, GR or GTR. After further stratified analysis of the summary stage, it was observed that this effect gradually weakened with increased stage. For patients with distant summary stage, PR was more beneficial compared with GTR. This phenomenon was further analyzed and it was indicated that this may be associated with the fact that PR produces a smaller residual tumour volume compared with EB, which can slow the tumour growth rate. In addition, GTR is more traumatic for the patient compared with PR ([@b31-ol-0-0-11514]). Total surgical resection should be considered with caution by the surgeon, as it is strictly dependent on the anatomical location of the tumour, as well as the presence of patient comorbidities ([@b17-ol-0-0-11514]). Therefore, for different patients with astrocytoma, different and individual treatments are necessary.

There are limitations to the present study. Firstly, the SEER database is a retrospective dataset with its own retrospective study limitations. Secondly, the patients\' physical conditions were unclear and patients with several comorbidities may pursue more conservative treatment. Thirdly, there may be selection bias with patients receiving GTR compared with STR. This may be due to the surgeons who would consider the postoperative complications of GTR surgery for astrocytoma patients. In addition, for chemotherapy and radiotherapy, the present study does not distinguish whether adjuvant or neoadjuvant therapy was used and there is no information on the specific radiotherapy technique, including dose, fractionation and beam energy, or chemotherapy regimen used.

In the present study, it was demonstrated that the survival benefit of GTR was higher compared with unsuccessful or not attempted GTR, therefore more patients need to be encouraged to undergo GTR to improve OS and CSS times.
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![Number and proportion of surgical methods performed on patients with astrocytoma with different summary statuses between 2004 and 2015. (A) All patients, n=42,224. (B) Localized patients, n=33,090. (C) Regional patients, n=7,375. (D) Distant patients, n=594. (E) WHO grade I ([@b7-ol-0-0-11514]) patients, n=1,010. (F) WHO grade II patients, n=4,695. (G) WHO grade III patients, n=3,643. (H) WHO grade IV patients, n=32,876. WHO, World Health Organization; EB, excision biopsy; STR, subtotal resection; GR, gross resection; PR, partial resection; GTR, gross total resection.](ol-19-06-3761-g00){#f1-ol-0-0-11514}

![Number and proportion of different summary stages and WHO grades ([@b7-ol-0-0-11514]) between 2004 and 2015. (A) Different summary stages, n=42,224. (B) Different WHO grades, n=42,224. WHO, World Health Organization.](ol-19-06-3761-g01){#f2-ol-0-0-11514}

![Annual change in the proportion of different surgical methods performed on patients with astrocytoma between 2004 and 2015. EB, excision biopsy; STR, subtotal resection; GR, gross resection; PR, partial resection; GTR, gross total resection.](ol-19-06-3761-g02){#f3-ol-0-0-11514}

![Kaplan-Meier survival curves according to surgical method, summary stage and WHO grade ([@b7-ol-0-0-11514]) in patients with astrocytoma. (A and B) Overall survival (left) and cancer-specific survival (right) based on surgical method. (C and D) Overall survival (left) and cancer-specific survival (right) based on summary stage. (E and F) Overall survival (left) and cancer-specific survival (right) based on WHO grade. EB, excision biopsy; STR, subtotal resection; GR, gross resection; PR, partial resection; GTR, gross total resection; WHO, World Health Organization.](ol-19-06-3761-g03){#f4-ol-0-0-11514}

![OS and CSS curves of patients with astrocytoma according to the surgical method undergone at different summary stages. (A and B) OS (left) and CSS (right) in patients with localized summary stage. (C and D) OS (left) and CSS (right) in patients with regional summary stage. (E and F) OS (left) and CSS (right) in patients with distant summary stage. EB, excision biopsy; STR, subtotal resection; GR, gross resection; PR, partial resection; GTR, gross total resection; OS, overall survival; CSS, cancer-specific survival.](ol-19-06-3761-g04){#f5-ol-0-0-11514}

###### 

Overall survival and cancer-specific survival curves of patients with astrocytoma patients according to the surgical method undergone in different World Health organization grades ([@b7-ol-0-0-11514]). (A and B) OS (left) and CSS (right) in patients with grade I. (C and D) OS (left) and CSS (right) in patients with grade II. (E and F) OS (left) and CSS (right) in patients with grade III. (G and H) OS (left) and CSS (right) in patients with grade IV. EB, excision biopsy; STR, subtotal resection; GR, gross resection; PR, partial resection; GTR, gross total resection; OS, overall survival; CSS, cancer-specific survival.
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###### 

Characteristics of patients with astrocytoma stratified by surgical method.

  Characteristic                                            n (%)           No surgery, n (%)   EB, n (%)      STR, n (%)      GR, n (%)      PR, n (%)      GTR, n (%)     P-value^[a](#tfn1-ol-0-0-11514){ref-type="table-fn"}^
  --------------------------------------------------------- --------------- ------------------- -------------- --------------- -------------- -------------- -------------- -------------------------------------------------------
  Total patients                                            42,224          11,427 (27.1)       7,661 (18.1)   5,520 (13.1)    6,037 (14.3)   5,314 (12.6)   6,265 (14.8)   
  Age at diagnosis                                                                                                                                                          \<0.001
    18--40                                                  4,991 (11.8)    924 (18.5)          947 (19.0)     701 (14.0)      886 (17.8)     623 (12.5)     910 (18.2)     
    41--60                                                  14,445 (34.2)   3,028 (21.0)        2,736 (18.9)   2,035 (14.1)    2,198 (15.2)   2,043 (14.1)   2,405 (16.6)   
    61--80                                                  18,899 (44.8)   5,269 (27.9)        3,454 (18.3)   2,497 (13.2)    2,691 (14.2)   2,358 (12.5)   2,630 (13.9)   
    \>80                                                    3,889 (9.2)     2,206 (56.7)        524 (13.5)     287 (7.4)       162 (6.7)      290 (7.5)      320 (8.2)      
  Year of diagnosis                                                                                                                                                         \<0.001
    2004                                                    3,281 (7.8)     1,000 (30.5)        390 (11.9)     43 (1.3)        50 (1.5)       778 (23.7)     1,020 (31.1)   
    2005                                                    3,182 (7.5)     1,003 (31.5)        321 (10.1)     39 (1.2)        54 (1.7)       788 (24.8)     977 (30.7)     
    2006                                                    3,180 (7.5)     961 (30.2)          388 (12.2)     26 (0.8)        50 (1.6)       724 (22.8)     1,031 (32.4)   
    2007                                                    3,432 (8.1)     997 (29.1)          544 (15.9)     30 (0.9)        54 (1.6)       846 (24.7)     961 (28.0)     
    2008                                                    3,408 (8.1)     1,039 (30.5)        919 (27.0)     16 (0.5)        46 (1.3)       751 (22.0)     637 (18.7)     
    2009                                                    3,462 (8.2)     1,008 (29.1)        1,055 (30.5)   99 (2.9)        97 (2.8)       625 (18.1)     578 (16.7)     
    2010                                                    3,504 (8.3)     890 (25.4)          876 (25.0)     570 (16.3)      473 (13.5)     363 (10.4)     332 (9.5)      
    2011                                                    3,581 (8.5)     949 (26.5)          678 (18.9)     840 (23.5)      805 (22.5)     114 (3.2)      195 (5.4)      
    2012                                                    3,764 (8.9)     894 (23.8)          627 (16.7)     913 (24.3)      1,065 (28.3)   105 (2.8)      160 (4.3)      
    2013                                                    3,783 (9.0)     912 (24.1)          652 (17.2)     980 (25.9)      1,027 (27.1)   74 (2.0)       138 (3.6)      
    2014                                                    3,776 (8.9)     842 (22.3)          604 (16.0)     1,007 (26.7)    1,102 (29.2)   89 (2.4)       132 (3.5)      
    2015                                                    3,871 (9.2)     932 (24.1)          607 (15.7)     957 (24.7)      1,214 (31.4)   57 (1.5)       104 (2.7)      
  Sex                                                                                                                                                                       \<0.001
    Male                                                    2,4209 (57.3)   6,254 (25.8)        4,431 (18.3)   3,264 (13.95)   3,493 (14.4)   3,125 (12.9)   3,642 (15.0)   
    Female                                                  18,015 (42.7)   5,173 (28.7)        3,230 (17.9)   2,256 (12.5)    2,544 (14.1)   2,189 (12.2)   2,623 (14.6)   
  Ethnicity                                                                                                                                                                 \<0.001
    White                                                   3,7462 (88.7)   10,080 (26.9)       6,766 (18.1)   4,859 (13.0)    5,391 (14.4)   4,733 (17.4)   5,633 (15.0)   
    Black                                                   2,467 (5.8)     656 (26.6)          510 (20.7)     332 (13.5)      355 (14.4)     292 (16.4)     322 (13.1)     
    Other                                                   2,295 (5.4)     691 (30.1)          385 (16.8)     329 (14.3)      291 (12.7)     289 (17.3)     310 (13.5)     
  Marital status                                                                                                                                                            \<0.001
    Married                                                 2,5825 (61.2)   6,536 (25.3)        4,627 (17.9)   3,418 (13.2)    3,790 (14.7)   3,395 (13.1)   4,059 (15.7)   
    Unmarried                                               14,824 (35.1)   4,454 (30.0)        2,690 (18.1)   1,854 (12.5)    1,978 (13.3)   1,797 (12.1)   2,051 (13.8)   
    Unknown                                                 1,575 (3.7)     437 (27.7)          344 (21.8)     248 (15.7)      269 (17.1)     122 (7.7)      155 (9.8)      
  Urban-rural residence                                                                                                                                                     0.002
    Metropolitan                                            37,086 (87.8)   9,963 (26.9)        6,662 (18.0)   4,863 (13.1)    5,362 (14.5)   4,690 (12.6)   5,546 (15.0)   
    Non-metropolitan                                        5,138 (12.2)    1,464 (28.5)        999 (19.4)     657 (12.8)      675 (13.1)     624 (12.1)     719 (14.0)     
  Income                                                                                                                                                                    \<0.001
    Lower                                                   13,219 (31.3)   3,767 (28.5)        2,479 (18.8)   1,696 (12.8)    1,942 (14.7)   1,571 (11.9)   1,764 (13.3)   
    Middle                                                  14,937 (35.4)   4,142 (27.1)        2,648 (17.0)   1,931 (12.9)    2,170 (14.5)   2,007 (13.1)   2,341 (15.4)   
    Upper                                                   14,068 (33.3)   3,518 (25.7)        2,534 (18.8)   1,893 (13.5)    1,925 (13.7)   1,736 (12.7)   2,160 (15.7)   
  Summary stage                                                                                                                                                             \<0.001
    Localized                                               33,090 (78.4)   7,363 (22.3)        6,169 (18.6)   4,379 (13.2)    5,376 (16.2)   4,197 (12.7)   5,606 (16.9)   
    Regional                                                7,375 (17.5)    3,100 (42.0)        1,222 (16.6)   979 (13.3)      547 (7.4)      974 (13.2)     553 (7.5)      
    Distant                                                 594 (1.4)       225 (37.9)          112 (18.9)     94 (15.8)       51 (8.6)       63 (10.6)      49 (8.2)       
    Unstaged/unknown                                        1,165 (2.8)     739 (63.4)          158 (13.6)     68 (5.8)        63 (5.4)       80 (6.9)       57 (4.9)       
  WHO grade^[b](#tfn2-ol-0-0-11514){ref-type="table-fn"}^                                                                                                                   \<0.001
    I                                                       1,010 (2.4)     136 (13.5)          197 (19.5)     134 (13.3)      191 (18.9)     115 (11.4)     237 (23.5)     
    II                                                      4,695 (11.1)    1,770 (37.7)        868 (18.5)     407 (8.7)       520 (11.1)     564 (12.0)     566 (12.1)     
    III                                                     3,643 (8.6)     1,264 (34.7)        755 (20.7)     442 (12.1)      459 (12.6)     361 (9.9)      362 (9.9)      
    IV                                                      3,2876 (77.9)   8,257 (25.1)        5,841 (17.8)   4,537 (13.8)    4,867 (14.8)   4,274 (13.0)   5,100 (15.5)   
  Radiotherapy                                                                                                                                                              \<0.001
    Yes                                                     28,429 (67.3)   5,844 (20.6)        5,296 (18.6)   4,177 (14.7)    4,629 (16.3)   3,858 (13.6)   46,25 (16.3)   
    No                                                      13,795 (32.7)   5,583 (40.5)        2,365 (17.1)   1,343 (9.7)     1,408 (10.2)   1,456 (10.6)   1,640 (11.9)   
  Chemotherapy                                                                                                                                                              \<0.001
    Yes                                                     24,910 (59.0)   4,601 (18.5)        4,708 (18.9)   3,869 (15.5)    4,311 (17.3)   3,280 (13.2)   4,141 (16.6)   
    No                                                      17,314 (41.0)   6,826 (39.4)        2,953 (17.1)   1,651 (9.5)     1,726 (10.0)   2,034 (11.7)   2,124 (12.3)   

Comparison between different surgical methods

([@b7-ol-0-0-11514]). EB, excision biopsy; STR, subtotal resection; GR, gross resection; PR, partial resection; GTR, gross total resection.

###### 

Kaplan-Meier analysis overall survival and cancer-specific survival for patients with astrocytoma.

                                    Kaplan-Meier             Kaplan-Meier                
  ------------------------- ------- -------------- --------- -------------- ------------ ---------
  Age at diagnosis, years           12,929.451     \<0.001                  10,171.401   \<0.001
    18--40                  77.00                            112.00                      
    41--60                  15.00                            17.00                       
    61--80                  6.00                             8.00                        
    \>60                    2.00                             3.00                        
  Sex                               2.209          0.137                    4.125        0.042
    Male                    10.00                            13.00                       
    Female                  10.00                            12.00                       
  Ethnicity                         116.719        \<0.001                  143.124      \<0.001
    White                   10.00                            12.00                       
    Black                   11.00                            15.00                       
    Other                   14.00                            18.00                       
  Marital status                    7.893          0.019                    6.171        0.046
    Married                 11.00                            13.00                       
    Unmarried               8.00                             11.00                       
    Unknown                 10.00                            13.00                       
  Urban-rural residence             87.138         \<0.001                  72.102       \<0.001
    Metropolitan            11.00                            8.00                        
    Non-metropolitan        8.00                             6.00                        
  Income                            122.487        \<0.001                  82.768       \<0.001
    Lower                   9.00                             11.00                       
    Middle                  10.00                            12.00                       
    Upper                   11.00                            14.00                       
  Summary stage                     1,208.088      \<0.001                  1,097.821    \<0.001
    Localized               12.00                            14.00                       
    Regional                6.00                             7.00                        
    Distant                 4.00                             5.00                        
    Unstaged/unknown        5.00                             8.00                        
  WHO grade                         6,264.594      \<0.001                  5,846.311    \<0.001
    I                       --                               --                          
    II                      39.00                            66.00                       
    III                     20.00                            25.00                       
    IV                      8.00                             10.00                       
  Surgery                           3212.688       \<0.001                  2,281.789    \<0.001
    No surgery              4.00                             5.00                        
    EB                      11.00                            13.00                       
    STR                     12.00                            14.00                       
    GR                      17.00                            19.00                       
    PR                      10.00                            12.00                       
    GTR                     15.00                            17.00                       
  Radiotherapy                      1,377.534      \<0.001                  712.575      \<0.001
    Yes                     13.00                            15.00                       
    No                      3.00                             4.00                        
  Chemotherapy                      1,392.837      \<0.001                  697.593      \<0.001
    Yes                     14.00                            16.00                       
    No                      3.00                             5.00                        

MST, median survival time; OS, overall survival; CSS, cause-specific survival; EB, excision biopsy; STR, subtotal resection; GR, gross resection; PR, partial resection; GTR, gross total resection.

###### 

Risk factors for overall survival and cancer-specific survival for patients with astrocytoma.

                            OS                     CSS                              
  ------------------------- ---------------------- --------- ---------------------- ---------
  Age at diagnosis, years                                                           
    18--40                  Reference                        Reference              
    41--60                  2.29 (2.18--2.41)      \<0.001   2.24 (2.12--2.36)      \<0.001
    61--80                  3.85 (3.66--4.05)      \<0.001   3.66 (3.47--3.86)      \<0.001
    \>60                    5.85 (5.51--6.20)      \<0.001   5.47 (5.13--5.84)      \<0.001
  Ethnicity                                                                         
    White                   Reference                        Reference              
    Black                   0.92 (0.88--0.97)      0.001     0.87 (0.82--0.91)      \<0.001
    Other                   0.84 (0.80--0.88)      \<0.001   0.82 (0.77--0.86)      \<0.001
  Marital status                                                                    
    Married                 Reference                        Reference              
    Unmarried               1.10 (1.07--1.12)      \<0.001   1.08 (1.05--1.10)      \<0.001
    Unknown                 0.96 (0.91--1.02)      0.179     0.92 (0.86--0.98)      0.009
  Urban-rural residence                                                             
    Metropolitan            Reference                        Reference              
    Non-metropolitan        1.05 (1.01--1.09)      0.015     1.06 (1.02--1.11)      0.003
  Income                                                                            
    Lower                   Reference                        Reference              
    Middle                  0.94 (0.92--0.97)      \<0.001   0.97 (0.94--1.00)      0.055
    Upper                   0.88 (0.85--0.91)      \<0.001   0.89 (0.86--0.92)      \<0.001
  Summary stage                                                                     
    Localized               Reference                        Reference              
    Regional                1.43 (1.39--1.47)      \<0.001   1.46 (1.41--1.50)      \<0.001
    Distant                 1.49 (1.36--1.62)      \<0.001   1.53 (1.40--1.69)      \<0.001
    Unstaged/unknown        0.75 (0.70--0.80)      \<0.001   0.75 (0.70--0.81)      \<0.001
  WHO grade                                                                         
    I                       Reference                        Reference              
    II                      5.01 (4.23--5.95)      \<0.001   6.49 (5.21--8.09)      \<0.001
    III                     10.09 (8.50--11.98)    \<0.001   14.23 (11.40--17.75)   \<0.001
    IV                      18.34 (15.50--21.70)   \<0.001   26.39 (21.22--32.82)   \<0.001
  Surgery                                                                           
    No surgery              1.45 (1.41--1.50)      \<0.001   1.43 (1.38--1.49)      \<0.001
    EB                      Reference                        Reference              
    STR                     0.95 (0.92--0.99)      0.022     0.96 (0.92--1.00)      0.068
    GR                      0.72 (0.69--0.75)      \<0.001   0.72 (0.69--0.76)      \<0.001
    PR                      1.04 (1.00--1.08)      0.038     1.04 (1.00--1.08)      0.069
    GTR                     0.80 (0.77--0.83)      \<0.001   0.80 (0.77--0.83)      \<0.001
  Radiotherapy                                                                      
    Yes                     Reference                        Reference              
    No                      1.61 (1.56--1.67)      \<0.001   1.58 (1.52--1.64)      \<0.001
  Chemotherapy                                                                      
    Yes                     Reference                        Reference              
    No                      1.55 (1.50--1.60)      \<0.001   1.49 (1.45--1.55)      \<0.001

HR, hazard ratio; CI, confidence interval; OS, overall survival; CSS, cause-specific survival; EB, excision biopsy; GR, gross resection; PR, partial resection; STR, subtotal resection; GTR, gross total resection.

###### 

Subgroup analyses stratified by summary stage and grade for overall survival and cancer-specific survival for patients with.

                          OS                            CSS                          
  -------------- -------- ------------------- --------- -------- ------------------- ---------
  Localized                                                                          
    No surgery   4.00     1.54 (1.48--1.60)   \<0.001   6.00     1.51 (1.44--1.57)   \<0.001
    EB           12.00    Reference           --        15.00    Reference           --
    STR          13.00    0.99 (0.94--1.04)   0.611     15.00    1.00 (0.96--1.05)   0.879
    GR           17.00    0.73 (0.70--0.77)   \<0.001   19.00    0.74 (0.70--0.77)   \<0.001
    PR           11.00    1.07 (1.02--1.12)   0.002     13.00    1.07 (1.02--1.12)   0.007
    GTR          16.00    0.82 (0.79--0.86)   \<0.001   14.00    0.82 (0.79--0.86)   \<0.001
  Regional                                                                           
    No surgery   3.00     1.31 (1.22--1.41)   \<0.001   4.00     1.30 (1.20--1.40)   \<0.001
    EB           7.00     Reference           --        8.00     Reference           --
    STR          10.00    0.85 (0.78--0.94)   0.001     11.00    0.83 (0.75--0.92)   \<0.001
    GR           12.00    0.70 (0.63--0.79)   \<0.001   13.00    0.71 (0.62--0.80)   \<0.001
    PR           8.00     0.94 (0.86--1.03)   0.175     9.00     0.95 (0.86--1.04)   0.277
    GTR          11.00    0.68 (0.61--0.76)   \<0.001   13.00    0.67 (0.59--0.75)   \<0.001
  Distant                                                                            
    No surgery   2.00     1.21 (0.94--1.55)   0.133     2300     1.20 (0.92--1.56)   0.177
    EB           5.00     Reference           --        5.00     Reference           --
    STR          8.00     0.79 (0.58--1.07)   0.131     10.00    0.72 (0.52--1.01)   0.056
    GR           9.00     0.65 (0.45--0.94)   0.023     13.00    0.58 (0.39--0.88)   0.010
    PR           5.00     0.68 (0.49--0.94)   0.021     7.00     0.63 (0.44--0.90)   0.012
    GTR          6.00     0.75 (0.53--1.06)   0.099     7.00     0.69 (0.47--1.00)   0.051
  Grade I                                                                            
    No surgery            NA                  0.112              NA                  0.169
    EB           --       Reference           --                 Reference           --
    STR          --       NA                  0.564              NA                  0.388
    GR           --       NA                  0.823              NA                  0.706
    PR           --       NA                  0.724              NA                  0.356
    GTR          --       NA                  0.885              NA                  0.310
  Grade II                                                                           
    No surgery   18.00    1.26 (1.13--1.40)   \<0.001   31.00    1.17 (1.04--1.32)   0.012
    EB           44.00    Reference           --        69.00    Reference           --
    STR          49.00    0.88 (0.73--1.06)   0.063     63.00    0.86 (0.70--1.05)   0.138
    GR           96.00    0.71 (0.58--0.86)   \<0.001   --       0.71 (0.57--0.88)   0.002
    PR           39.00    1.14 (0.99--1.31)   0.062     64.00    1.05 (0.90--1.23)   0.516
    GTR          104.00   0.77 (0.66--0.90)   0.001     --       0.78 (0.66--0.92)   0.004
  Grade III                                                                          
    No surgery   8.00     1.45 (1.30--1.62)   \<0.001   10.00    1.51 (1.34--1.69)   \<0.001
    EB           20.00    Reference           --        24.00    Reference           --
    STR          35.00    0.85 (0.72--1.01)   0.064     47.00    0.83 (0.69--1.00)   0.050
    GR           72.00    0.55 (0.45--0.67)   \<0.001   75.00    0.55 (0.45--0.68)   \<0.001
    PR           29.00    1.02 (0.87--1.18)   0.836     33.00    1.02 (0.87--1.20)   0.809
    GTR          78.00    0.57 (0.48--0.68)   \<0.001   119.00   0.57 (0.48--0.69)   \<0.001
  Grade IV                                                                           
    No surgery   3.00     1.45 (1.40--1.51)   \<0.001   4.00     1.42 (1.37--1.48)   \<0.001
    EB           9.00     Reference           --        10.00    Reference           --
    STR          10.00    0.98 (0.94--1.02)   0.339     11.00    0.99 (0.95--1.04)   0.703
    GR           14.00    0.74 (0.71--0.77)   \<0.001   16.00    0.75 (0.710.78)     \<0.001
    PR           9.00     1.03 (0.99--1.08)   0.138     10.00    1.04 (0.99--1.08)   0.116
    GTR          13.00    0.82 (0.79--0.87)   \<0.001   14.00    0.83 (0.79--0.86)   \<0.001

HR, hazard ratio; CI, confidence interval; OS, overall survival; CSS, cause-specific survival; EB, excision biopsy; STR, subtotal resection; GR, gross resection; PR, partial resection; GTR, gross total resection.
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